Can China Innovate? Degron Aims For First-In-Class TPD Therapies
New Funds For Novel Platform
Fresh out of an impressive new round of financing and armed with $32m, Shanghai's Degron Therapeutics is aiming for nothing but first-in-class treatments. Its co-founder and CSO shares views on creating original innovative drugs from inside China in an exclusive interview with Scrip.
